Conference abstractPublished 17 Aug 2015
Development of Gummi Drugs of Aripiprazole
University of Shizuoka, Japan.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
About a half of patients with schizophrenia have poor medication adherence, resulting in recurrence of schizophrenia. Gummi drugs, shaped confectionary dosage forms, can be easily chewed and swallowed without water. Schizophrenic patients could easily take this formulation daily, improving medication adherence. Our goal was to develop gummi drugs containing aripiprazole (ARP) using commercially available ARP products (Abilify®; Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan). Three ARP formulations (orally disintegrating tablets, ODTs; powder formulations; and oral solutions) were modified to gummy drugs (OD-G, PW-G, and OS-G, respectively). Furthermore, we prepared improved OD-G (ARP-G), which contained high ARP content. In terms of appearance, OD-G and ARP-G were transparent white, PW-G was shiny opaque white, and OS-G was chalky white with a rough surface. Pharmaceutical characteristics of ARP-G were demonstrated to be suitable for hospital formulations, and ARP-G could be stored for ≤1 month. We assumed patients taking gummi drugs will chew and divide them into several pieces. Therefore, the dissolution test was conducted with ARP-G divided into 2 to 8 pieces. As the number of divisions increased, the speed of dissolution also increased. The average dissolution rate of ARP-G divided into 8 pieces was similar to that of tablets and ODTs. There were no significant differences in Cmax and the AUC(0-24) between ARP-G and tablets after oral administration in Beagle dogs. In conclusion, we were able to develop ARP gummi drugs by using commercially available products as a hospital formulation. Because patients can easily take gummy drugs daily, ARP-G will help improve medication adherence .
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Shinya Uchida”